Skip to content

Pressure-Volume Loop Assessment in Valvular Heart Disease

Invasive Hemodynamic Study of Structural Heart Diseases: A Monocentric, Non-Randomized Approach

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07112391
Acronym
VHD-PV-loop
Enrollment
70
Registered
2025-08-08
Start date
2025-09-04
Completion date
2027-09-04
Last updated
2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Interventional Cardiology, Structural Heart Disease

Keywords

Chronic heart failure, Structural heart disease, Interventional cardiology, Multimodality imaging

Brief summary

The VHD PV loop study intends to assess invasive right ventricular to pulmonary artery (RV-PA) coupling in patients with valvular heart disease (VHD). Invasive RV-PA coupling is measured by using conductance catheters, the gold standard assessment for ventricular physiology. Several non-invasive parameters have been reported as surrogates for this complex physiological entity, but none of them has been tested against the gold-standard in this population. Based on this, our main objective is to assess the correlation of imaging derived RV-PA coupling in comparison to the invasive measurement.

Detailed description

This study aims to improve the assessment of right ventricular (RV) function in patients with valvular heart disease (VHD), by validating non-invasive imaging parameters of right ventricular to pulmonary artery (RV-PA) coupling against invasive measurements using conductance catheters-the gold standard for evaluating RV hemodynamics. Currently available non-invasive tools do not always provide reliable evaluation of RV-PA coupling. This study seeks to identify accurate imaging surrogates to support clinical decision-making, particularly in conditions such as secondary mitral regurgitation, tricuspid regurgitation, and right-sided structural heart disease. By correlating non-invasive indices-such as tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio (TAPSE/PASP) and RV strain-with invasive data, the study may enhance diagnostic strategies, improve patient care, and support future prognostic and therapeutic investigations. Data may also contribute to post hoc analyses in existing registries and help refine our understanding of RV adaptation in structural heart disease.

Interventions

OTHERObservational Invasive Hemodynamic Assessment

Collection and analysis of invasive hemodynamic data obtained through routine cardiac catheterization performed as part of standard care. No intervention is mandated by the study protocol.

Sponsors

Fédération Française de Cardiologie
CollaboratorOTHER
Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (≥ 18 years old); * Patients with severe structural heart disease (meeting at least one of the following three criteria): * Heart failure with moderate-to-severe or severe secondary mitral regurgitation * At least severe tricuspid regurgitation * Significant pulmonary valve stenosis and/or regurgitation

Exclusion criteria

* Patients under legal guardianship or protection (e.g., guardianship, trusteeship, or any other legal protection measure); * Pregnant or breastfeeding women; * Vulnerable individuals (e.g., persons deprived of liberty, adults under legal protection); * Contraindication to right heart catheterization, including: * Known proximal venous occlusion of the superior or inferior vena cava territory * Presence of a mobile mass in the right heart chambers * Significant tricuspid stenosis

Design outcomes

Primary

MeasureTime frameDescription
Correlation with non-invasive echocardiographic parametersDuring right heart catheterization (Day 1)Assessment of diagnostic performances of TAPSE/PAPS, RVFWLS/PAPS and FAC/PAPS ratios compared to Ees/Ea ratio.

Countries

France

Contacts

Primary ContactRobin LE RUZ, MD, PhD
robin.leruz@chu-nantes.fr02. 53.48.28.36

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026